Neurofilament light protein as a blood biomarker for Huntington's disease in children

- 4
- 5 Lauren M Byrne^{1*†}, Jordan L Schultz^{2†}, Filipe B Rodrigues¹, Ellen van der Plas²,
- 6 Douglas Langbehn², Peg Nopoulos^{2††}, Edward J Wild^{1*††}
- 7

8 Affiliations:

- 9 1. Huntington's Disease Centre, UCL Queen Square Institute of Neurology,
- 10 University College London, London WC1N 3BG
- 12. Department of Psychiatry, Carver College of Medicine at the University of Iowa,
- 12 200 Hawkins Drive, Iowa City, IA 52242
- 13
- 14
- ¹⁵ [†]These authors contributed equally as first authors of this study.
- 16 ⁺⁺ These authors contributed equally as senior authors of this study
- 17 * Corresponding authors: lauren.byrne.14@ucl.ac.uk; e.wild@ucl.ac.uk;
- 18
- 19
- 20 Current main text Word count: 18003
- 21

22 Abstract

- 23 Juvenile-onset Huntington's disease (JoHD) is a rare, particularly devastating form of
- 24 Huntington's Disease (HD) for which clinical diagnosis is challenging and robust
- 25 outcome measures are lacking. Neurofilament light protein (NfL) in plasma has
- 26 emerged as a prognostic biomarker for adult-onset HD. We report that plasma NfL is
- 27 elevated in JoHD and premanifest HD mutation-carrying children. Quantifying plasma
- 28 NfL may improve clinical diagnosis and therapeutic trial design in the pediatric
- 29 population.

31 Main text

32	Juvenile-onset HD (JoHD) is a devastating form of Huntington's Disease (HD) that
33	manifests before the age of 21 ¹ . While the underlying pathology of CAG repeat
34	expansions in HTT exon 1 is similar to adult-onset HD (AoHD), JoHD has typically much
35	larger expansions. JoHD has unique disease features including prominent rigidity,
36	dystonia, and bradykinesia, and tends to progress rapidly. There are no disease-
37	modifying therapies for HD but numerous targeted therapeutics are in advanced trials ² .
38	JoHD is ultra-rare (approximately 5 per million ³), contributing to a lack of robust clinical
39	scales or biomarkers that could facilitate clinical trials in this population. Further, initial
40	manifestations of JoHD often overlap with normal variability in childhood or
41	adolescence, or with prevalent juvenile disorders such as depression, anxiety, ADHD,
42	Tourette's syndrome, complicating difficult decisions about diagnosis and genetic
43	testing of minors ¹ .
44	
45	Similar to other neurological diseases, plasma neurofilament light chain protein (NfL)
46	has emerged as a biomarker for AoHD that strongly correlates with clinical, cognitive
47	and MRI measures ⁴ . Baseline plasma NfL concentration increases early and predicts
48	subsequent HD progression and brain atrophy ^{4–7} . In a cohort of young adult premanifest
49	HD (preHD) mutation carriers, on average 24 years from estimated onset, NfL
50	concentrations in CSF and plasma were the earliest detectable alterations in HD ⁸ .
51	
52	Despite being a robust biomarker for AoHD ^{4–7} , NfL has yet to be evaluated in JoHD or

53 in children and adolescent HD mutation carriers who will develop HD in adulthood but

54 have no disease manifestations (preHD). We quantified plasma NfL in a unique cohort 55 of 9 JoHD subjects, 30 preHD and 61 mutation-free control children and adolescents. 56 57 Characteristics of the age-matched cohort are in Supplementary Table 1. We assessed 58 potential confounding demographics (age: Extended Data Fig. 1a; parental 59 socioeconomic status: Extended Data Fig. 1b; sex: Extended Data Fig. 1c; Tanner 60 stage [puberty classification system]: Extended Data Fig. 1d), finding little evidence for 61 the impact of healthy development on plasma NfL concentrations. 62 63 We investigated whether plasma NfL was elevated in JoHD. JoHD patients had 64 significantly higher plasma NfL than controls (32.46 pg/mL, [95% Confidence interval 65 (95%CI) 18.08 – 58.27], versus 4.76 pg/mL, [95%CI 4.33 – 5.23] respectively; 66 p<0.0001; Fig. 1a). In JoHD, plasma NfL rose with age on a trajectory significantly 67 distinct from controls (Age*Group: 1.09 pg/mL/year [Confidence interval (95%CI) 1.02-68 1.16], p=0.013; Fig. 1b). A cutoff of 11.1 pg/mg identified 91% of JoHD cases and 96% 69 of controls (AUC 0.96; Fig. 1c). We also evaluated the relationship between plasma NfL 70 and JoHD clinical measures (Supplementary Table 2). There were no associations 71 between plasma NfL and UHDRS total motor scale, the JoHD Motor scale, or its 72 components, with the exception of the Bradykinesia Drinking measure which had a 73 positive association with plasma NfL (LMER Est. 1.25, [95%CI 0.46 – 2.05] p=0.017). 74 However, this did not survive multiple comparisons correction (false discovery rate 75 p=0.103). There was a significant, positive association between disease duration and 76 plasma NfL concentration (LMER Est. 2.18 [95%CI 0.31 – 4.05] p=0.045). No significant

associations were found between plasma NfL and disease burden score (DBS) or brainvolumes in JoHD.

79

80	Next, we investigated plasma NfL in preHD children. Overall, the age trajectories of NfL
81	in preHD compared to healthy controls were not statistically different from one another
82	(Age*group: 1.02 pg/mL/year [95%Cl 0.97-1.06], p=0.534; Fig. 1d). We subdivided
83	preHD by their predicted years to onset (YTO) to assess whether plasma NfL was
84	elevated in children closer to their predicted onset. The characteristics of the YTO
85	groupings are presented in Supplementary Table 3. The mean plasma NfL
86	concentration in controls was 4.76 pg/mL, (95%CI 4.33 – 5.23), which did not differ
87	significantly from preHD 40-60 YTO (5.21 pg/mL, [95%CI 3.96 – 6.84]), 30-40 YTO
88	(4.53 pg/mL, [95%Cl 3.45 – 5.94]), or 20-30 YTO (4.10 pg/mL, [95%Cl 3.32 – 5.05]).
89	However, the preHD groups that were 15-20 years from onset (7.03 pg/mL [95%CI 5.34
90	– 9.25]) and within 15 years from predicted onset (10.07 pg/mL [95%Cl 7.51 – 13.52])
91	both had significantly higher plasma NfL than controls (t=3.31, p_{FDR} =0.0033 and t=3.72,
92	p _{FDR} =0.0015, respectively; Fig. 1e).

93

In a combined group of HD mutation carriers (preHD+JOHD), we explored the
relationship between plasma NfL and brain volume, including whole brain, caudate and
putamen volume, which are of primary pathological importance in HD. There were
significant negative associations (Supplementary Table 4; Fig. 1f-h) between plasma
NfL and whole-brain (LMER Est. -0.90 [Cl -1.64 – -0.16] p=0.020; Fig. 1f), caudate
(LMER Est. -0.06 [95%Cl -0.08 – -0.03] p=0.0001; Fig. 1g) and putamen volumes

- 100 (LMER Est. -0.09 [95%CI -0.12 -0.06] p<0.0001; Fig. 1h). When exploring at the
- 101 associations limiting the analysis to JoHD and preHD children within 20 years from
- 102 predicted motor onset, the respective slopes of these associations were greater but,
- 103 given the reduced sample size, only caudate (LMER Est. -0.12 [95%CI -0.18 -0.05]
- 104 p=0.0040; Fig. 1g) and putamen (LMER Est. -0.14 [95%CI -0.21 -0.07] p=0.0025; Fig.
- 105 1h) volumes remained significant (Supplementary Table 4).



106

a, Plasma NfL groupwise differences and b, modelled plasma NfL trajectories with age in JoHD compared to controls.
c, Receiver operating characteristic curve for Plasma NfL discriminating JoHD from controls. d, modelled plasma NfL trajectories with age in preHD and e, YTO groupwise plasma NfL differences compared to control children. Plasma NfL associations with f, whole brain g, caudate and h, putamen volumes in all HD mutation carriers or those with JoHD and within 20 YTO. Data points are raw plasma NfL. Statistics were generated from LMER models with effects per participant and per family (intercepts) and using Satterthwaite approximation for degrees of freedom. P values in e are adjusted for multiple comparisons. For f-h, all brain volumes were %ICV; models additionally included a covariate to account for different scanners; and model statistics are presented in Supplementary Table 4. NfL, neurofilament light protein; JoHD, Juvenile-onset Huntington's disease; preHD, premanifest HD; YTO, years to onset; ICV, intracranial volume; LMER, linear mixed effects regression; MD, mean difference.

¹⁰⁷ Fig. 1 Plasma NfL in JoHD and children at-risk for HD.

- 119 We combined the KidsHD and KidsJoHD cohorts with HD-CSF a longitudinal cohort of
- 120 80 adult HD mutation carriers and controls to compare the course of plasma NfL
- 121 throughout life in health, JoHD and adult-onset Huntington's disease (Fig. 2a). Plasma
- 122 NfL initially begins to rise from approximately DBS 200.



123

124 Fig. 2 Plasma NfL throughout the HD mutation carrier lifespan.

125 Plasma NfL plotted against **a**. age and **b**. disease burden score in both the Kids cohort and HD-CSF cohort. Data points are raw plasma NfL. NfL, neurofilament light protein.

128 The elevation and distinct age trajectory of plasma NfL in JoHD patients compared to 129 healthy control children are consistent with those observed in adult onset HD^{4,6,7}. 130 Associations with clinical measures were modest, although this may be driven by lack of 131 power and limitations in JoHD clinical measures. Furthermore, as previously reported in 132 AoHD $^{4-7}$, plasma NfL was inversely associated with brain volumes in children with HD 133 mutations, whether JoHD or preHD. Plasma NfL elevation in preHD children within 20 134 years from predicted onset is consistent with increases reported in a young adult HD 135 cohort. Morphological neurodevelopment differences in the striatum⁹ may limit the utility 136 of MRI to distinguish between the neurodevelopmental and neurodegeneration effects 137 of the HD mutation. NfL could provide insights into the point where neurodevelopment is 138 the predominant concern, potentially helping to inform decisions around the timing of 139 disease-modifying interventions Collectively, these findings suggest two potential 140 applications of NfL: 1) identification of high-risk children for early diagnosis and 141 intervention; and 2) assessing neuroprotection in cohorts of all ages. By evaluating NfL 142 across a wide age range, we can begin to estimate plasma NfL thresholds indicative of 143 neurodegeneration. This could be of value in informing ethically-challenging decisions 144 about which at-risk children showing possible disease manifestations should undergo 145 genetic testing. We conclude that plasma NfL shows promise as a blood biomarker of 146 JoHD and may facilitate clinical trial design in this rare and understudied population.

147

149 References

150	1.	Oosterloo, M., Bijlsma, E. K., de Die-Smulders, C. & Roos, R. A. C. Diagnosing
151		Juvenile Huntington's Disease: An Explorative Study among Caregivers of
152		Affected Children. Brain Sci. 10, 155 (2020).
153	2.	Tabrizi, S. J., Flower, M. D., Ross, C. A. & Wild, E. J. Huntington disease: new
154		insights into molecular pathogenesis and therapeutic opportunities. Nature
155		Reviews Neurology vol. 16 529–546 (2020).
156	3.	Quarrell, O., O'Donovan, K. L., Bandmann, O. & Strong, M. The prevalence of
157		juvenile Huntington's disease: A review of the literature and meta-analysis. PLoS
158		<i>Currents</i> vol. 4 (2012).
159	4.	Byrne, L. M. et al. Neurofilament light protein in blood as a potential biomarker of
160		neurodegeneration in Huntington's disease: a retrospective cohort analysis.
161		<i>Lancet Neurol.</i> 16 , 601–9 (2017).
162	5.	Johnson, E. B. et al. Neurofilament light protein in blood predicts regional atrophy
163		in Huntington disease. <i>Neurology</i> 90 , e717–e723 (2018).
164	6.	Byrne, L. M. et al. Evaluation of mutant huntingtin and neurofilament proteins as
165		potential markers in Huntington's disease. <i>Sci. Transl. Med.</i> 10 , eaat7108 (2018).
166	7.	Rodrigues, F. B. et al. Mutant huntingtin and neurofilament light have distinct
167		longitudinal dynamics in Huntington's disease. Sci. Transl. Med. 12, 2888 (2020).
168	8.	Scahill, R. I. et al. Biological and clinical characteristics of gene carriers far from
169		predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a
170		cross-sectional analysis. Lancet Neurol. 19, 502–512 (2020).
171	9.	van der Plas, E. et al. Abnormal brain development in child and adolescent

- 172 carriers of mutant huntingtin. *Neurology* **93**, E1021–E1030 (2019).
- 173 10. Tereshchenko, A. *et al.* Brain structure in juvenile-onset Huntington disease.
- 174 *Neurology* **92**, E1939–E1947 (2019).
- 175 11. Byrne, L. M. et al. Cerebrospinal fluid neurogranin and TREM2 in Huntington's
- 176 disease. *Sci. Rep.* **8**, 4260 (2018).
- 177 12. Lowe, A. J. *et al.* Cerebrospinal fluid endo-lysosomal proteins as potential
- biomarkers for Huntington's disease. *PLoS One* **15**, (2020).
- 179 13. Horton, M. C. et al. Assessment of the Performance of a Modified Motor Scale as
- Applied to Juvenile Onset Huntington's Disease. *J. Huntingtons. Dis.* 8, 181–193
 (2019).
- 182 14. Penney, J. B., Vonsattel, J.-P., Macdonald, M. E., Gusella, J. F. & Myers, R. H.
- 183 CAG repeat number governs the development rate of pathology in Huntington's
 184 disease. *Ann. Neurol.* 41, 689–692 (1997).
- 185 15. Langbehn, D., Brinkman, R., Falush, D., Paulsen, J. & Hayden, M. A new model
- 186 for prediction of the age of onset and penetrance for Huntington's disease based
- 187 on CAG length. *Clin. Genet.* **65**, 267–277 (2004).
- 188 16. Khalil, M. *et al.* Serum neurofilament light levels in normal aging and their
- association with morphologic brain changes. *Nat. Commun.* **11**, 1–9 (2020).

191 Extended Data



193 Extended Data Fig. 1 Plasma NfL in healthy development and potential confounding demographics.

Plasma NfL concentrations are plotted against a, age b, parental socioeconomic status c, sex and d, Tanner stage (puberty) in healthy control individuals (n=61). Data was available from multiple timepoints for some individuals (83 observations). P-values were generated from linear mixed effects regression models with a random participant effect (intercept). Pairwise tests were post-hoc t-tests using Satterthwaite's method. Raw NfL values are presented. Models used natural log transformed NfL data and was back-transformed for a, the age model. NfL, neurofilament light protein; LMER, linear mixed effects regression.

200

- 201
- 202

203 Acknowledgements

- We would like to thank all the participants who took part, providing their time, data and samples to make this work possible.
- 206 Funding
- 207 This work was supported by the Medical Research Council UK (to EJW), the CHDI
- 208 Foundation (to EJW), the Huntington's Disease Society of America (to LMB), the
- 209 Hereditary Disease Foundation (to LMB), and the National Institute of Health (NIH)
- 210 grant NS094387 Growth and Development of the Striatum in Huntington's Disease (to
- 211 PN).

212 Author Contributions

- EJW, PN, LMB, JLS and DL were responsible the conception and design of the work;
- 214 LMB, JLS, FBR and EVP were involved in the acquisition of data; LMB and JLS
- 215 performed the data analysis; EJW, PN, LMB, JLS and DL were involved in the
- 216 interpretation of data; LMB drafted the first manuscript draft with JLS and incorporated
- 217 coauthor revisions. All authors approved the submitted version of the manuscript
- 218 Competing Interests statement
- 219 LMB, FBR and EJW are full-time UCL employees. LMB receives salary support from the
- Huntington's disease Society of America, and has provided consultancy for F.
- Hoffmann-La Roche AG, Genentech, Novartis International AG, Annexon Inc and GLG.
- 222 JLS receives salary support from the National Center for Advancing Translational
- 223 Sciences (NIH KL2TR002536) and the Michael J. Fox Foundation for Parkinson's
- 224 Research. FBR receives salary support from CHDI Foundation, and has provided

225 consultancy to GLG and Roche. E.J.W. reports grants from Medical Research Council 226 UK, CHDI Foundation, and F. Hoffmann-La Roche Ltd. during the conduct of the study 227 and personal fees from F. Hoffman-La Roche Ltd., Triplet Therapeutics, PTC 228 Therapeutics, Shire Therapeutics, Wave Life Sciences, Mitoconix, Takeda 229 Pharmaceuticals Ltd., and Logus 23. All honoraria for these consultancies were paid 230 through the offices of UCL Consultants Ltd., a wholly owned subsidiary of University 231 College London. University College London Hospitals NHS Foundation Trust has 232 received funds as compensation for conducting clinical trials for Ionis Pharmaceuticals, 233 Pfizer, and Teva Pharmaceuticals. and Stroke, the CHDI Foundation, University College 234 of London, and from the Wellcome Trust. During the past 12 months, he has served as 235 a paid statistical consultant for the design of Huntington's Disease trials for Novartis AG, 236 Voyager Therapeutics, Spark therapeutics, and Takeda Pharmaceutical Company 237 Limited. He has also been a paid consultant to Trinity Life Sciences. PN and EVP report 238 no competing interests.

240 Online methods

241 Study design

242 This retrospective analysis involved quantification of plasma NfL using available blood 243 samples and matching phenotypic data that were collected as part of the KidsHD and 244 KidsJoHD studies – observational studies at the University of Iowa that recruited 245 children and young adults with a family history of HD or with Juvenile Onset HD 246 respectively; as well as healthy control volunteers with no known family history of HD. 247 Recruitment began in May 2009 and was completed in January 2018. All KidsHD/JoHD 248 participants provided either saliva or blood for genetic testing which was for research 249 purposes only; results were not revealed to participants, their families, clinicians, or 250 researchers. Both studies implemented an accelerated longitudinal design where some 251 participants attended multiple visits at 1-2 year intervals and so had repeated measures 252 as previously described^{9,10}. The Institutional Review Board at the University of Iowa 253 approved the KidsHD and KidsJoHD studies. The parents or guardians of participants 254 who were less than 18 years old provided written consent and the children provided 255 written assent. Participants who were 18 years or older provided written consent. 256 We combined plasma NfL data from both KidsHD and KidsJoHD with previously 257 published plasma NfL data from the longitudinal HD-CSF cohort to visually assess how 258 NfL fluctuates over the lifespan of the HD mutation carrier. HD-CSF has been 259 extensively described^{6,11,12} (online protocol: DOI: 10.5522/04/11828448.v1).

260 Participants

261	For the current analysis, at-risk participants from Kids-HD were classified as
262	premanifest HD (preHD) mutation carriers if their CAG repeat length was \geq 36 and
263	healthy controls if <36. JoHD was defined as a UHDRS Total Motor Score \ge 10 before
264	the age of 21 in the context of the HD mutation and a confirmed diagnosis by a trained
265	neurologist. Plasma samples were available for 30 preHD (44 visits), 60 healthy controls
266	(82 visits) and nine JoHD participants (11 total visits). Clinical severity in JoHD was
267	assessed using the UHDRS total motor score, the JoHD Motor scale ¹³ – an adapted
268	version of UHDRS total motor score which weighs JoHD-specific components higher –
269	and disease duration (determined by length of time from clinical diagnosis to time of
270	study visit in years). Disease burden score (DBS) – an arithmetic composite of CAG and
271	age that encompasses the cumulative burden of the CAG expansion [Age * (cAG-35.5)]
272	 – was used as a known predictor of HD progression¹⁴.
273	The preHD group was divided into subgroups based on their predicted years to motor
274	onset (YTO) into the following groups: 40-60 YTO; 30-40 YTO; 20-30 YTO; 15-20 YTO;
275	<15 YTO. This was calculated using the using their CAG repeat length and age in the
276	formula from Langbehn and colleagues ¹⁵ .

277

 $YTO = Age_n - (21.54 + e^{(9.556 - [0.1460 * CAG])})$

This formula was used only for participants with a CAG repeat length of 36-49. For
participants with a CAG repeat length of 50 or above, the Langbehn formula was slightly
modified to provide a more accurate estimate of the predicted years to onset.
Participants were excluded from either study if they had a history of a major neurologic
illness, brain surgery, or significant head trauma.

283

284 Plasma Sample Collection and Storage

- 285 KidsHD/JoHD blood samples were collected in EDTA Vacutainer tubes (BD). All
- samples were coded with a unique study ID and were sent to the University of Iowa
- 287 Diagnostic Laboratories. Samples were briefly stored on ice and then centrifuged at
- 288 2,000g for x minutes. Plasma was decanted before being centrifuged at 3,000g at 4°C
- for 15 minutes then pipetted into 1.2-mL cryotubes in 500 uL aliquots and frozen and
- 290 stored at -80°C before being shipped.
- 291

292 NfL Quantification

- 293 KidsHD/JoHD plasma NfL concentrations were measured using the commercially
- available NF-Light[®] assay kit from on the Simoa HD-1 analyzer platform as per the
- 295 manufacturer's instructions (Quanterix, Lexington). NfL was quantified in duplicate for all
- plasma samples. The intra-assay coefficient of variation (CV) was 6.5% and inter-assay
- 297 CV was 1.65%. HD-CSF plasma NfL was previously quantified and published as per
 298 Rodrigues et al⁷.
- 299

300 Image Acquisition and processing

301 The structural imaging acquisition methods have been described previously⁹. A 3T

302 Siemens Trio TIM (Siemens AG, Munich, Germany) machine was used to acquire

- 303 images prior to June 2016 (n=33). After June 2016, a 3T General Electric Discovery
- 304 MR750w (GE Medical Systems, Chicago, IL) was used (n=17). Full details regarding
- 305 image processing have been previously described by van der Plas, et al⁹.

306

307 Statistical Analysis

308 In accordance with previous evaluations of plasma NfL, all available NfL concentrations 309 underwent natural log-transformation to account for non-normal distribution^{4,6}. We 310 assessed potentially counfounding demographics and measures of healthy 311 development on plasma NfL. None of the variables assessed had an effect on plasma 312 NfL. However, since NfL has been shown to be associated with healhty aging, we 313 included age as a covariate for subsequent analyses¹⁶. For the primary analyses-of-314 interest, we performed linear mixed effects regression (LMER) models. The accelerated 315 longitudinal design of KidsHD/JoHD allows for modeling trajectories of development 316 over time while statistically accounting for the correlation that occurs from repeat visits 317 from individuals⁹. All LMER models also included random effects per family to account 318 for siblings in the dataset. P-values were estimated using Satterthwaite approximation 319 for degrees of freedom throughout.

320

For groupwise comparisons, we compared LMER model adjusted mean plasma NfL values between groups. In these models, within-subject and residual variances were estimated separately for the various groups via iteratively re-weighted least squares. This was done to account for sizable differences in variation between the groups. We adjusted for multiple comparisons using false-discovery-rate (FDR) corrections.

326

327 The age*group interaction was evaluated to determine group differences in age-328 trajectories of plasma NfL. To assess associations with clinical measures, LMER

329 models were constructed with plasma NfL as the independent variable and clinical 330 measures as the dependent variables. LMER models for DBS – a predictor of HD 331 progression – included NfL as the dependent variable. Age was not included as a 332 covariate in either of the models that investigated the relationship between disease 333 duration or DBS and plasma NfL to avoid collinearity, since age was used to calculate 334 these variables. For neuroimaging measures, brain volumes were the dependent 335 variables and NfL independent within the LMER models to permit the addition of 336 scanner as a covariate to account for scanner differences. All brain volumes were 337 presented as percent of intracranial volume (ICV). 338 339 We created a receiver operating characteristic curve by performing a generalized 340 binomial regression model with plasma NfL as the independent predictor variable for 341 whether or not a participant was a healthy control or had JoHD. We calculated 342 Youden's Index by adding the sensitivity and specificity at all available plasma NfL 343 levels. The maximal specificity cutoff point was at 0.964 and the maximal sensitivity 344 cutoff point was at 0.909 and this point correlated with a plasma NfL cutoff point of 11.1 345 pg/mL. These analyses were performed using the pROC package in RStudio (version 346 1.16.2)

347

Groupwise analyses were performed using the PROC MIXED function within SAS (v9.4,
SAS Institute Inc, Cary, NC, USA). All other models were performed in RStudio version
1.3.159 using the ImerTest version 3.1.

351 Data availability

- 352 The data that support the findings of this study are available from the corresponding
- 353 author upon reasonable request.

355 Supplementary material

356 Supplementary Table 1 Baseline Cohort Characteristics of KidsHD and KidsJoHD

P-values for continuous variables were generated from one-way analyses of variance. P-values for categorical
variables were generated from Pearson Chi-Square analyses. Values are presented as mean ± SD unless otherwise
stated. preHD, premanifest Huntington's disease; JoHD, Juvenile-onset Huntington's disease. SD, Standard
deviation; CAG, Cytosine-Adenine-Guanine; BMI, Body mass index; SES, socioeconomic status, measured by the
Hollingshead Scale; NfL, neurofilament light protein.

	Controls	preHD	JoHD	P-Value
N (total visits)	61 (83)	30 (44)	9 (11)	N/A
Age	12.75 ± 3.71	14.00 ± 3.12	16.48 ± 6.38	0.40
Males, N (%)	23 (37.7)	10 (33.3)	5 (55.6)	0.483
CAG	20.33 ± 4.39	43.90 ± 4.47	72.11 ± 12.67	< 0.0001
BMI	22.14 ± 7.48	21.92 ± 5.13	21.51 ± 6.22	0.963
Tanner Stage, N (%)				0.337
0	15 (22.2)	4 (13.3)	2 (22.2)	
1	4 (6.6)	0 (0)	0 (0)	
2	4 (6.6)	1 (3.3)	0 (0)	
3	12 (19.7)	5 (16.7)	0 (0)	
4	16 (26.2)	15 (50.0)	4 (44.4)	
5	10 (16.4)	5 (16.7)	3 (33.3)	
Parental SES, N (%)				0.062
1	0 (0)	0 (0)	0 (0)	
2	36 (59.0)	14 (46.7)	2 (22.2)	
3	22 (36.1)	14 (46.7)	4 (44.4)	
4	2 (3.3)	2 (6.7)	2 (22.2)	
5	1 (1.6)	0 (0)	1 (11.1)	
Plasma NfL (pg/mL)	4.71 ± 1.55	5.05 ± 1.57	35.16 ± 2.95	<0.0001

- - -

Supplementary Table 2 Clinical measures and their associations with plasma NfL in JoHD

P-values were generated from linear mixed effects regression models with effects per participant and per family

374 375 376 377 378 379 (intercepts) and using Satterthwaite approximation for degrees of freedom. Values are presented as the beta estimate of the model relative to the log-transformed plasma NfL concentration. The models that assessed the relationship between disease duration and disease burden score did not include age as a covariate, as both independent variables are calculated using age. All brain volumes were corrected for intracranial volume and models investigating the relationship between plasma NfL and brain volumes included a covariate to account for different scanners. NfL, neurofilament light protein; UHDRS, Unified Huntington's Disease Rating Scale; TMS, total motor

score; JoHD, Juvenile-onset Huntington's disease.

Clinical measures	Association with plasma NfL					
	N (total visits)	Estimate	Confidence interval	P-value		
UHDRS TMS	9 (11)	7.02	-13.91 - 27.94	0.522		
JoHD Motor Scale	9 (11)	3.87	-0.56 - 8.30	0.119		
Chorea	9 (11)	0.07	-0.57 - 0.71	0.832		
Bradykinesia Handtapping	9 (11)	0.05	-0.96 - 1.05	0.934		
Bradykinesia Drinking	9 (10)	1.25	0.46 - 2.05	0.017		
Tremors	9 (11)	0.41	-0.38 - 1.19	0.333		
Disease duration	9 (11)	1.19	0.03 - 2.35	0.045		
Disease burden score	9 (11)	1.00	-0.01 - 2.01	0.347		
Whole Brain Volume	9 (10)	-3.10	-7.19 - 0.99	0.180		
Putamen Volume	9 (10)	-0.10	-0.20 - 0.01	0.112		
Caudate Volume	9 (10)	-0.07	-0.15 - 0.01	0.116		

396 Supplementary Table 3 Baseline Cohort Characteristics by years to onset groupings

P-values for continuous variables were generated from one-way analyses of variance. P-values for categorical variables were generated from Pearson Chi-Square analyses. Values are presented as mean ± SD unless otherwise stated. SD, Standard deviation; CAG, Cytosine-Adenine-Guanine; YTO, years to onset; BMI, Body mass index; SES, socioeconomic status, measured by the Hollingshead Scale; NfL, neurofilament light protein.

	Controls	40-60 YTO	30-40 YTO	20-30 YTO	15-20 YTO	<15 YTO	P-Value
N (total	61 (83)	9 (15)	10 (12)	7 (9)	2 (4)	2 (4)	NA
visits)							
Age	12.75 ± 3.71	13.99 ± 2.07	13.47 ± 3.93	13.33 ± 2.98	15.04 ± 2.65	17.96 ± 3.12	0.355
Female,	23 (37.7)	4 (44.4)	8 (80.0)	6 (85.7)	1 (50.0)	1 (50.00)	0.488
N (%)							
CAG	20.33 ± 4.39	39.78 ± 0.97	42.60 ± 0.84	46.71 ± 2.29	49.00 ± 1.41	54.00 ± 7.07	< 0.0001
YTO	N/A	50.39 ± 6.23	36.38 ± 2.03	24.392 ± 2.87	17.96 ± 0.79	11.06 ± 1.93	< 0.0001
BMI	22.14 ± 7.48	22.63 ± 5.88	20.68 ± 4.83	21.99 ± 4.86	18.23 ± 1.16	28.42 ± 1.30	0.295
Tanner							0.280
Stage							
0	15 (22.2)	0 (0.0)	3 (30.0)	1 (14.3)	0 (0.0)	0 (0.0)	
1	4 (6.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	
2	4 (6.6)	1 (11.1)	0 (0.0)	0 (0.0)	0(0.0)	0 (0.0)	
3	12 (19.7)	4 (44.4)	0 (0.0)	0 (0.0)	1 (50.0)	0 (0.0)	
4	16 (26.2)	4 (44.4)	5 (50.0)	4 (57.1)	1 (50.0)	1 (50.0)	
5	10 (16.4)	0 (0.0)	2 (20.0)	2 (28.6)	0 (0.0)	1 (50.0)	
Parental							0.366
SES, N	0 (0)						
(%)	36 (59.0)	5 (55.6)	7 (70.0)	1 (14.3)	1 (50.0)	0 (0.0)	
2	22 (36.1)	3 (33.3)	3 (30.0)	5 (71.4)	1 (50.0)	2 (100.0)	
3	2 (3.3)	1 (11.1)	0 (0.0)	1 (14.3)	0(0.0)	0 (0.0)	
4	1 (1.6)						
Plasma	4.71 ± 1.55	4.81 ± 1.55	4.81 ± 1.67	4.43 ± 1.32	6.42 ± 1.48	9.97 ± 1.63	0.211
NfL							

Supplementary Table 4 Plasma NfL associations with brain volume in HD mutation carriers

413 414 P-values were generated from linear mixed effects regression models with random effects per participant and per

family (intercepts), age as a covariate and using Satterthwaite approximation for degrees of freedom. Values are

presented as the beta estimate of the model relative to the log-transformed plasma NfL concentration. All brain

416 volumes were corrected for intracranial volume and models investigating the relationship between plasma NfL and

brain volumes included a covariate to account for different scanners. NfL, neurofilament light protein; HD,

Huntington's disease; JoHD, Juvenile-onset Huntington's disease.

Clinical measures	Association with plasma NfL - All HD mutation carriers				Association with plasma NfL – JoHD and within 20 YTO			
	N (total visits)	Estimate	Confidence interval	P-value	N (total visits)	Estimate	Confidence interval	P-value
Whole Brain Volume	35 (49)	-0.90	-1.640.16	0.020	12 (17)	-1.46	-3.67 – 0.74	0.207
Caudate Volume	35 (49)	-0.06	-0.080.03	0.0001	12 (17)	-0.12	-0.180.05	0.0040
Putamen Volume	35 (49)	-0.09	-0.120.06	< 0.0001	12 (17)	-0.14	-0.210.07	0.0025





